Alpha 2.0
Login Register
» Articles » PMID: 21933908

Sensor-augmented Pump Therapy for A1C Reduction (STAR 3) Study: Results from the 6-month Continuation Phase

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2011 Sep 22
PMID 21933908
Citations 42
Authors
Richard M Bergenstal
William V Tamborlane
Andrew Ahmann
John B Buse
George Dailey
Stephen N Davis
Carol Joyce
Bruce A Perkins
John B Welsh
Steven M Willi
Michael A Wood
Affiliations
Soon will be listed here.
Abstract

OBJECTIVE To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.

Citing Articles

Evaluating the Impact of Continuous Glucose Monitoring on Erectile Dysfunction in Type 1 Diabetes: A Focus on Reducing Glucose Variability and Inflammation.

Tecce N, Menafra D, Progano M, Tecce M, Pivonello R, Colao A Healthcare (Basel). 2024; 12(18).

PMID: 39337164 PMC: 11430976. DOI: 10.3390/healthcare12181823.

Long-Term Benefits of an Integrated Continuous Glucose Monitoring and Insulin Pump System for Emergency Admissions, Hospitalization, and Metabolic Control in a Cohort of People With Diabetes: Retrospective Cohort Study.

Omeara M, Mateus Acuna J, Uribe A JMIR Diabetes. 2023; 8:e46880.

PMID: 37610810 PMC: 10483304. DOI: 10.2196/46880.

Glycaemic control and novel technology management strategies in pregestational diabetes mellitus.

Newman C, Ero A, Dunne F Front Endocrinol (Lausanne). 2023; 13:1109825.

PMID: 36714590 PMC: 9877346. DOI: 10.3389/fendo.2022.1109825.

Guideline Development for Medical Device Technology: Issues for Consideration.

Battelino T, Brosius F, Ceriello A, Cosentino F, Green J, Kellerer M J Diabetes Sci Technol. 2022; 17(6):1698-1710.

PMID: 35531901 PMC: 10658688. DOI: 10.1177/19322968221093355.

RT-CGM in conjunction with CSII vs MDI in optimizing glycaemic control in T1DM: Systemic review and meta-analysis.

William J, McCluskey J, Gleeson N Endocrinol Diabetes Metab. 2022; 5(2):e00324.

PMID: 35118826 PMC: 8917862. DOI: 10.1002/edm2.324.

References
1.
Agrawal P, Welsh J, Kannard B, Askari S, Yang Q, Kaufman F . Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol. 2011; 5(5):1137-41. PMC: 3208869. DOI: 10.1177/193229681100500514. View
2.
Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H . Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care. 2009; 32(12):2245-50. PMC: 2782985. DOI: 10.2337/dc09-0750. View
3.
Slover R, Welsh J, Criego A, Weinzimer S, Willi S, Wood M . Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2011; 13(1):6-11. DOI: 10.1111/j.1399-5448.2011.00793.x. View
4.
Bergenstal R, Tamborlane W, Ahmann A, Buse J, Dailey G, Davis S . Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010; 363(4):311-20. DOI: 10.1056/NEJMoa1002853. View
5.
Davis S, Horton E, Battelino T, Rubin R, Schulman K, Tamborlane W . STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther. 2010; 12(4):249-55. PMC: 2883476. DOI: 10.1089/dia.2009.0145. View